Virtual Event, Worldwide : 5 - 6 December 2023
Kristian Helin, ICR, London, UK
Mark Dawson, Peter MacCallum Cancer Centre, Melbourne, Australia
Ho Man Chan, Head of Epigenetics, Research and Development AstraZeneca, Arlington, USA
Jingwen Zhang, Associate Director, AstraZeneca, Waltham, USA
Cigall Kadoch, Harvard Medical School, Boston, USA
Cigall Kadoch, Ph.D., is an academic leader and entrepreneur in the biomedical sciences. She is an Associate Professor of Pediatric Oncology at the Dana-Farber Cancer Institute, Institute Member and Epigenomics Program Co-Director at the Broad Institute of MIT and Harvard, and she is an Investigator at Howard Hughes Medical Institute. She is also the Scientific Founder of Foghorn Therapeutics (NASDAQ: FHTX), where she currently serves on the Scientific Advisory Board.
Dr. Kadoch established her independent laboratory in 2014, at age 28, one of the youngest scientists ever appointed to the Harvard Medical School faculty, immediately following completion of her Ph.D. studies at Stanford University. She is a leading expert in chromatin and gene regulation and is internationally recognized for her groundbreaking studies in these areas. Specifically, her laboratory studies the structure and function of nuclear protein complexes that govern DNA architecture and gene expression, called chromatin remodeling complexes, perturbations in which cause a range of human cancers and neurodevelopmental disorders.
Dr. Kadoch has received numerous prestigious awards and research grants for her work, including the NIH Director’s New Innovator Award, the American Association for the Advancement of Science (AAAS) Martin and Rose Wachtel Cancer Research Prize, the American Association for Cancer Research Outstanding Achievement in Basic Cancer Research, and was recently named a finalist for the Blavatnik National Awards. Additionally, she has been named to the Forbes 30 Under 30 list, MIT Technology Review 35 Innovators Under 35, Popular Science Brilliant 10, and Business Insider Top 30 Young Leaders in Biopharma.
Professor Ricky Johnstone received his PhD from the University of Melbourne in 1993 and after a postdoc at Harvard Medical School returned to Melbourne to establish the Gene Regulation Laboratory at the Peter MacCallum Cancer Centre in 2000.
Professor Johnstone is the Executive Director Cancer Research at the Peter MacCallum Cancer Centre overseeing ~700 staff and students and plays a key role in strategic decision making across the organisation. He has published more than 245 peer-reviewed papers, was awarded an NHMRC Senior Principal Research Fellowship in 2015 and in 2011 was promoted to Full Professor in the Department of Pathology at the University of Melbourne.
Prof Johnstone is an internationally renowned cancer researcher who has utilized genetic mouse models of hemopoietic malignancies and solid tumors to understand the epigenetic and transcriptional changes that underpin tumor onset and progression and to develop new therapies that target epigenetic and transcriptional regulatory proteins.
Prof Johnstone has recently discovered how epigenetic based-agents can engage the host immune system to drive prolonged therapeutic responses.
Céline Vallot, Ph.D., is a group leader at Institut Curie since 2017.
Her team studies epigenomes at single-cell resolution in breast cancers to understand non genetic mechanisms of tumor evolution. Combining experimental and computational approaches, they study the dynamics of epigenomes during treatment and the early phases of tumorigenesis.
Her group made recent key contributions to our understanding of cancer epigenetics, mapping cancer epigenomes for the first time at single-cell resolution and more recently demonstrating that repressive histone modifications condition tolerance to chemotherapy in triple-negative breast cancers. The team also develops computational tools to analyze and model single cell epigenomic and transcriptomic datasets to identify common vulnerabilities across patients.
Céline received an ERC Starting Grant in 2020, and her team is supported by the Bettencourt Schueller Foundation. Recipient of the 2022 CNRS Innovation Medal, she co-founded the Institut Curie Single Cell Initiative, enabling scientists to analyze individual cells in space and time at various scales (DNA, RNA , epigenomes, proteins). She is also the Scientific Founder of the company One Biosciences, where she currently serves on the Scientific Advisory Board.
Professor Ernesto Guccione received his PhD from ICGEB/SISSA in Trieste (2004) and after a postdoc at IEO, Milan in the Amati Lab (2004-2008) started his own lab at IMCB/A*STAR in Singapore (2008).
Dr. Guccione is now a Full Professor with tenure at Mount Sinai Icahn School of Medicine and has a long-standing interest in understanding basic mechanisms of transcriptional and post-transcriptional regulation in order to identify therapeutic opportunities in oncology. In the past 20 years he has established himself as a leader in the field of Arginine Methylation, Cancer Epigenomics and Transcriptomics.
In particular the research in the Guccione Lab focuses on dissecting the role of oncogenic Protein Methyltransferases (PMTs), such as Protein Arginine Methyltransferases (i.e. PRMT6 and PRMT5), SET domain containing proteins (i.e. EZH2, G9a) and PRDMs (i.e. PRDM9, PRDM10 and PRDM15).
Dr. Guccione has expertise in biochemistry, molecular biology, and preclinical oncological studies using mouse models of cancer (DLBCL, AML, HCC and CRC) and tumor organoids (HCC and CRC). In addition, he is the co-Director the Bioinformatics for Next Generation Sequencing (BiNGS) Shared Resource Facility to provide NGS computational and statistical analysis for TCI-affiliated faculty members.
To date, Dr. Guccione has published >100 peer-reviewed papers, is the inventor of several patents and the scientific co-founder of two biotech startup company: ImmuNOA Pte.Ltd., focusing on improving T cell immunotherapy and Prometeo Therapeutics, focusing small molecule therapeutics.
Dr. Sangeeta Goswami is a physician-scientist at the Department of Genitourinary Medical Oncology and the Department of Immunology, Division of Cancer Medicine, at the University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Dr. Goswami obtained her Medical degree from the Gauhati Medical College in Assam, India and PhD in Immunology from the Baylor College of Medicine in Houston, Texas, USA. She completed her Internal Medicine Residency from University of Pittsburgh Medical Center (UPMC) and Medical Oncology Fellowship from MD Anderson Cancer Center.
Dr. Goswami has published numerous original research articles and reviews in high-impact journals such as Nature Medicine, Nature Immunology, Science, Nature Reviews Immunology, and Science Translational Medicine which enabled development of novel combination immunotherapy to treat cancer patients.
Her clinic is focused on treating patients with renal cell carcinoma and urothelial carcinoma. Her laboratory in the Department of Immunology focuses on understanding the cellular state and plasticity of the tumor-immune ecosystem and its role in determining response to immune checkpoint therapy. Dr. Goswami has designed multiple investigator-initiated clinical trials based on her pre-clinical data and currently leading them as a principal investigator.
Recently, she was elected to be a part of the “Extended Leadership Team” for the Break Through Cancer (BTC) GBM team, a research alliance between The University of Texas MD Anderson Cancer Center (MDACC), Dana Farber Cancer Institute, MIT, Johns Hopkins and Memorial Sloan Kettering Cancer Center. As a part of this multi-disciplinary alliance, Dr. Goswami will lead the discovery science work delineating myeloid cell biology to explore therapeutic avenues in GBM. She received numerous awards including Andrew Sabin Award in 2021 for high risk-high impact research for emerging leaders.
Oliver has overall responsibility for developing STORM’s target discovery platform and for the delivery of small molecule drugs from its emerging drug discovery pipeline. Oliver worked closely with scientific founders Professors Tony Kouzarides and Eric Miska to secure the initial £12m series A investment that launched STORM, and subsequently joined the company full time in October 2016.
Prior to STORM, Oliver was Programme Director at the National Institute for Health Research (NIHR), where he led the Translational Research Partnerships (TRPs) initiative and other industry-focused collaboration programmes in experimental medicine and early drug development. He served as Vice President Biology at Cellzome until the company’s acquisition by GSK in 2012, and as Director of Biology at UCB Pharma until 2008.
Oliver has over 15 years’ drug discovery experience in inflammation, neurology and oncology. He holds a degree in Biochemistry from the Free University Berlin and a PhD in Biochemistry and Cell Biology from the Institute of Cancer Research in London.
Eytan M. Stein, MD is the Chief of the Leukemia Service, Associate Attending Physician, Clinical Investigator, and Director of the Program for Drug Development in Leukemia on the Leukemia Service at Memorial Sloan Kettering Cancer Center. He conducts novel, phase I clinical trials of compounds that target the genetic and epigenetic basis of myeloid malignancies.
Dr. Stein led the clinical studies of the IDH2 inhibitor Enasidenib and the IDH1 Inhibitor Ivosidenib in patients with relapsed and refractory AML that led to their FDA approval in 2017 and 2018, respectively. He also leads a variety of phase 1 clinical trials and serves as the lead investigator at Memorial Sloan Kettering for the BEAT AML master clinical trial.
His current research focuses on elucidating mechanisms of resistance to IDH inhibitors and the use of Menin inhibitors in patients with MLL-rearranged acute leukemia.
His work has been published in journals such as Nature, Nature Medicine, The New England Journal of Medicine, JAMA Oncology, Cancer Discovery and Blood. In addition, he serves on the Editorial Boards of Blood and Leukemia and Lymphoma.
Dr. Kathrin Bernt, MD is a clinician scientist at the University of Pennsylvania and the Children’s Hospital of Philadelphia. She is an expert in KMT2A – rearranged leukemias, and epigenetic and transcriptional mechanisms in hematopoiesis and leukemia. Her clinical focus in on leukemias and lymphomas in children.
Dr. Bernt is leading an R01 funded, independent research group since 2012, first at the University of Colorado, then the University of Pennsylvania. She received her MD degree from Humboldt University in Berlin, Germany. Dr. Bernt completed residency at Baylor College of Medicine / Texas Children’s Hospital and fellowship at Boston Children’s Hospital / Dana Farber Cancer Institute / Harvard Medical School.
Dr. Bernt's goal is to further the understanding of the role of transcriptional regulation in pediatric hematopoietic stem cell biology and leukemia and translate findings into novel therapies. Dr. Bernt has made numerous seminal contributions to our understanding of the role of epigenetic modifiers in leukemias, including KMT2A, DOT1L, elongation complex members, and the polycomb repressive complex 2. Her most recent work has focused on the role of intrinsically disordered domains in transcription control in cancer.
Dr. Bernt has received numerous awards, including the American Society of Clinical Investigation (ASCI) Young Scientist Award and the International Society of Pediatric Oncology (SIOP) Translational Research Award.
Dietary requirements (in-person events only)
Please indicate any special dietary requirements here. We will try to cater to all dietary requirements and we will write to you if there is any problem.
Sharing your details with others
Please click below if you agree we can share your name, email and postal address with participants and exhibitors, who may use them to contact you.
Please note: you have selected NOT to share your details with participants and exhibitors.
You can click above to change this.
We will use the email address in your EACR account to communicate with you. However, during the checkout process you will need to enter the name and contact details of the person paying for your registration, if this is different to your own details. Please make sure you have this information to hand.
Terms and Conditions
Please read our Membership and Events Terms and Conditions before completing your registration.
Photography and video
Please note that we will be taking photographs and video at the conference for publicity and marketing purposes. If you do not wish to take part please inform the photographer.
The EACR is grateful for the continued support of its Industry Partners: